Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 8/20 | 0.46 |
| ▸ | CTSS | P25774 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1937079 | 1.00 | CTSK (0.46) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL3683654 | 1.00 | CTSK (0.46) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL330004 | 1.00 | CTSK (0.46) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL1937084 | 1.00 | CTSK (0.46) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL13685180 | 0.99 | CTSK (0.47) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL1935450 | 0.99 | CTSK (0.47) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL1935453 | 0.99 | CTSK (0.47) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL1943039 | 0.94 | CTSK (0.48) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL1943040 | 0.94 | CTSK (0.48) | CTSKCTSSALDH1A1TSHRHDAC4 | |
| SCHEMBL11975698 | 0.89 | CTSK (0.45) | CTSKCTSSALDH1A1HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 410 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2025-10-14 | — | — | US | disclosed |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2023-03-30 | — | — | US | disclosed |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2022-10-18 | — | — | US | disclosed |
| US-20220227806-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2022-07-21 | — | — | US | disclosed |
| CN-112689507-A | Amino acid compounds having unbranched linkers and methods of use thereof | 普利安特治疗公司 | 2021-04-20 | — | — | CN | disclosed |
| WO-2020247736-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIVERSITY OF MASSACHUSETTS (US) | 2020-12-10 | — | — | WO | disclosed |
| US-20200087265-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2020-03-19 | — | — | US | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-2780026-B1 | HCV NS3 PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2004037855-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-05-06 | — | — | WO | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| US-20040002448-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2004-01-01 | — | — | US | disclosed |
| US-20030224977-A1 | Macrocyclic peptides active against the hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-12-04 | — | — | US | disclosed |
| WO-2003099274-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-04 | — | — | WO | disclosed |
| US-6608027-B1 | Macrocyclic small peptides of low molecular weight that are inhibitory to NS3 protease of hepatitis C virus | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2003-08-19 | — | — | US | disclosed |
| WO-2003064455-A2 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| EP-1169339-A1 | MACROCYCLIC PEPTIDES INHIBITING THE HEPATITIS C VIRUS NS3 PROTEASE | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000059929-A1 | MACROCYCLIC PEPTIDES ACTIVE AGAINST THE HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030224977-A1 | Macrocyclic peptides active against the hepatitis C virus | CTRL, CPN1, CTRC | CTSK 124/4885CTSS 34/4885ALDH1A1 2718/4885 |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | CTSK 93/4885CTSS 58/4885ALDH1A1 1277/4885 |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | HAVCR2, LIPC, ZC3HAV1 | CTSK 251/4885CTSS 295/4885ALDH1A1 576/4885 |
| US-20200087265-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | CTSK 93/4885CTSS 58/4885ALDH1A1 1277/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | CTSK 531/4885CTSS 466/4885ALDH1A1 308/4885 |
| US-12441762-B2 | Hepatitis c virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | CTSK 93/4885CTSS 58/4885ALDH1A1 1277/4885 |
| US-20220227806-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | CTSK 93/4885CTSS 58/4885ALDH1A1 1277/4885 |
| US-20040002448-A1 | Macrocyclic peptides active against the hepatitis C virus | VIP, FURIN, RNASE1 | CTSK 444/4885CTSS 232/4885ALDH1A1 1770/4885 |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | CTSK 93/4885CTSS 58/4885ALDH1A1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.